Abstract

Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC). One of the most exciting new ways to find potential resistance markers involves running functional genetic screens, such as CRISPR, followed by manual triage of significantly enriched genes. This triage process to identify ‘high value’ hits resulting from the CRISPR screen involves manual curation that requires specialized knowledge and can take even experts several months to comprehensively complete. To find key drivers of resistance faster we build a recommendation system on top of a heterogeneous biomedical knowledge graph integrating pre-clinical, clinical, and literature evidence. The recommender system ranks genes based on trade-offs between diverse types of evidence linking them to potential mechanisms of EGFRi resistance. This unbiased approach identifies 57 resistance markers from >3,000 genes, reducing hit identification time from months to minutes. In addition to reproducing known resistance markers, our method identifies previously unexplored resistance mechanisms that we prospectively validate.

Resistance to EGFR inhibitors presents a major obstacle in treating non-small cell lung cancer. Here, the authors develop a recommender system ranking genes based on trade-offs between diverse types of evidence linking them to potential mechanisms of EGFRi resistance.

Details

Title
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer
Author
Gogleva Anna 1 ; Polychronopoulos Dimitris 2   VIAFID ORCID Logo  ; Pfeifer, Matthias 3 ; Poroshin Vladimir 4 ; Ughetto Michaël 5 ; Martin, Matthew J 3 ; Thorpe, Hannah 3 ; Bornot Aurelie 6 ; Smith, Paul D 3   VIAFID ORCID Logo  ; Sidders Ben 2 ; Dry, Jonathan R 7   VIAFID ORCID Logo  ; Ahdesmäki Miika 2 ; McDermott Ultan 3   VIAFID ORCID Logo  ; Papa Eliseo 1 ; Bulusu, Krishna C 2   VIAFID ORCID Logo 

 AI Engineering, R&D IT, AstraZeneca, Biological Insight Knowledge Graph (BIKG), Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 Oncology R&D, AstraZeneca, Early Computational Oncology, Research and Early Development, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 Oncology R&D, AstraZeneca, Bioscience, Research and Early Development, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 IGNITE, AstraZeneca, NLP Lab, Enterprise AI Services, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 AI Engineering, R&D IT, AstraZeneca, Biological Insight Knowledge Graph (BIKG), Gothenburg, Sweden (GRID:grid.418151.8) (ISNI:0000 0001 1519 6403) 
 Discovery Sciences, R&D, AstraZeneca, Data Sciences & Quantitative Biology, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 Oncology R&D, AstraZeneca, Early Computational Oncology, Research and Early Development, Waltham, USA (GRID:grid.418152.b) (ISNI:0000 0004 0543 9493) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2644715050
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.